Acute Hepatic Porphyria (AHP)
Acute hepatic porphyrias (AHPs) are a group of rare genetic disorders that result in enzyme deficiencies, disrupting the normal heme biosynthetic pathway. This can cause accumulation the neurotoxic porphyrin precursors, δ-ALA and PBG.
Featured Learning Zones
Biosimilars are uniquely placed to change clinical practice in the fields of gastroenterology, rheumatology, and dermatology. The adoption of biosimilars can improve patient access to the most appropriate treatment, at the optimum time, to ensure the best possible long-term disease outcomes.
AHPs are associated with potentially life-threatening acute attacks characterised by a range of debilitating symptoms including severe, diffuse abdominal pain, nausea, weakness and constipation. Patients may also experience a range of similarly non-specific chronic symptoms and therefore AHPs are frequently mistaken for other diseases including acute abdomen, infections, inflammatory bowel disease, acute cholecystitis, appendicitis, pancreatitis and intestinal occlusion.
Timely diagnosis of AHP is crucial, as delays in delivering appropriate treatment may have serious consequences for the long-term health of patients and many of the medications used to treat other gastrointestinal disorders may worsen the symptoms of AHP. AHP can be diagnosed using a PBG urine test, and testing should be considered in all patients presenting with recurrent abdominal pain of unknown origin.
Currently, treatment of AHP involves avoidance of precipitating factors, and administration of intravenous hemin in cases of acute attacks severe enough to warrant hospitalisation.
To find out more about AHP visit our dedicated Learning Zone, which includes further information on symptoms, diagnosis and treatment of this condition.
Related news and insights
Bristol Myers Squibb announced that the European Commission (EC) has approved Opdivo (nivolumab) in combination with fluoropyrimidine- and platinum-based combination chemotherapy for the first-line treatment of adult patients with HER2-negative advanced or metastatic gastric, gastroesophageal junction (GEJ), or esophageal adenocarcinoma (EAC) whose tumors express PD-L1 with a combined positive score (CPS) of more than 5.
Mirum Pharmaceuticals, Inc. announced that the FDA has approved Livmarli (maralixibat) oral solution for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) one year of age and older.